More Stories

Informist, Tuesday, Jul. 21, 2026

By Durgesh Nandan

MUMBAI – Specialty chemicals maker Jubilant Ingrevia Ltd. is expected to report a significant on-year rise in its net profit for the June quarter despite the spike in raw material costs due to the US-Iran war, according to brokerages tracking the company. The rise in the net profit is attributed to better pricing of chemical intermediates and revenue growth in specialty chemicals and nutrition and health solutions businesses.

The company's consolidated net profit for the June quarter is likely to rise over 69% on year to INR 1.27 billion, according to the average of estimates from four brokerages. Sequentially, the bottom line is expected to rise over 47%. The highest estimate for company's net profit is INR 1.98 billion from Motilal Oswal Financial Services Ltd. and the lowest is INR 1.00 billion from Nuvama Wealth Management Ltd.

Jubilant Ingrevia is expected to report consolidated revenues of INR 11.87 billion for the quarter, up over 14% on year and slightly up from INR 11.79 billion sequentially, according to the average of estimates. The highest estimate for the consolidated revenues is INR 12.74 billion from Kotak Securities Ltd. and the lowest estimate is INR 9.63 billion from Motilal Oswal.

Jubilant Ingrevia is expected to report a healthy quarter due to improved spreads on acetic anhydride and ethyl acetate, Nuvama said. Ethyl acetate is a sweet-smelling chemical widely used as a solvent for paints, coatings, inks, and medicines. Acetic anhydride is a chemical reagent used in the production of medications, textiles, and dyes.

The specialty chemical maker's bottom line is likely to be supported by the agricultural contract development and manufacturing organisation and higher realisations in the acetyl business, Nuvama said. Jubilant Ingrevia's June quarter earnings before interest, tax, depreciation, and amortisation are expected to rise 45% to INR 2.22 billion, according to the average of estimates. On a sequential basis, the company's EBITDA is likely to rise over 29%.  

"We are expecting a sequential growth in revenue and EBITDA in coming quarters, starting with Q1FY27 itself," the company had said after detailing its March quarter earnings. "... the construction of Gajraula Multi Purpose Plant is progressing well, this will further strengthen our contract development and manufacturing organization growth roadmap." 

Jubilant Ingrevia had stocked raw materials before the war, the management had said in an conference call with analysts after its March quarter earnings. This protected the company from high raw material costs in the March quarter which were caused by the war in West Asia and is also expected to benefit it in the June quarter.

The specialty chemical sector's profitability is likely to contract in the June quarter due to high prices of raw material as companies with exposure to West-Asia faced supply disruptions. This led to shipment delays and elevated freight costs, brokerages said.

Jubilant Ingrevia will detail its June quarter earnings Wednesday. Tuesday, shares of the company closed at INR 763.80 apiece on the National Stock Exchange, up nearly 4% from Monday.

Of the five research reports on the company available with Informist, four have a "buy" recommendation on the stock with an average target price of INR 881. This is over 15% higher than the closing price Tuesday. One brokerage has a "hold" recommendation with a target price of INR 647. Shares of the company are up nearly 9% since it released its March quarter earnings.

Following are the June quarter earnings estimates, in INR billion, for Jubilant Ingrevia from four brokerages in descending order of the estimate of the consolidated net profit:

End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Edited by Pankaj Aher

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.